Takashi Ishida

Summary

Affiliation: Nagoya City University
Country: Japan

Publications

  1. ncbi Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study
    Takashi Ishida
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Blood 120:1734-41. 2012
  2. ncbi Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study
    Takashi Ishida
    Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi, 467 8601, Japan
    J Clin Oncol 30:837-42. 2012
  3. ncbi CC chemokine receptor 4-positive diffuse large B-cell lymphoma involving the skin: a case report
    Takashi Ishida
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Japan
    Int J Hematol 82:148-51. 2005
  4. ncbi Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege
    Takashi Ishida
    Department of Internal Medicine and Molecular Science and Clinical Pathology, Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho chou, Mizuho ku, Nagoya shi, Aichi, Japan
    Cancer Res 66:5716-22. 2006
  5. ncbi Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model
    Asahi Ito
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi, Japan
    Cancer Immunol Immunother 58:1195-206. 2009
  6. ncbi The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma
    T Ishida
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Mizuho chou, Mizuho ku, Nagoya shi, Aichi, Japan
    Leukemia 20:2162-8. 2006
  7. ncbi Antibody therapy for Adult T-cell leukemia-lymphoma
    Takashi Ishida
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi 467 8601, Japan
    Int J Hematol 94:443-52. 2011
  8. ncbi A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model
    Fumihiko Sato
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi, 467 8601, Japan
    Cancer Immunol Immunother 59:1791-800. 2010
  9. ncbi Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo
    Asahi Ito
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467 8601, Japan
    J Immunol 183:4782-91. 2009
  10. ncbi Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome
    Hiroki Yano
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
    Clin Cancer Res 13:6494-500. 2007

Detail Information

Publications44

  1. ncbi Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study
    Takashi Ishida
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Blood 120:1734-41. 2012
    ..In conclusion, allogeneic HSCT not only with MAC but also with RIC is an effective treatment resulting in long-term survival in selected patients with ATL...
  2. ncbi Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study
    Takashi Ishida
    Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi, 467 8601, Japan
    J Clin Oncol 30:837-42. 2012
    ....
  3. ncbi CC chemokine receptor 4-positive diffuse large B-cell lymphoma involving the skin: a case report
    Takashi Ishida
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Japan
    Int J Hematol 82:148-51. 2005
    ..To the best of our knowledge, this report is the first of a CCR4-positive B-cell lymphoma. The present case provides new insights into the pathogenesis of skin involvement in B-cell lymphomas...
  4. ncbi Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege
    Takashi Ishida
    Department of Internal Medicine and Molecular Science and Clinical Pathology, Nagoya City University Graduate School of Medical Sciences, Kawasumi, Mizuho chou, Mizuho ku, Nagoya shi, Aichi, Japan
    Cancer Res 66:5716-22. 2006
    ....
  5. ncbi Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model
    Asahi Ito
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi, Japan
    Cancer Immunol Immunother 58:1195-206. 2009
    ..The second aim was to evaluate ADCC mediated in these humanized mice by the defucosylated anti-CC chemokine receptor 4 (CCR4) monoclonal antibody (mAb) which we have developed and which is now in phase I clinical trials...
  6. ncbi The CCR4 as a novel-specific molecular target for immunotherapy in Hodgkin lymphoma
    T Ishida
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Mizuho chou, Mizuho ku, Nagoya shi, Aichi, Japan
    Leukemia 20:2162-8. 2006
    ..Collectively, this study strongly indicates that anti-CCR4 mAb could be a novel treatment modality for patients with CCR4-positive HL...
  7. ncbi Antibody therapy for Adult T-cell leukemia-lymphoma
    Takashi Ishida
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi 467 8601, Japan
    Int J Hematol 94:443-52. 2011
    ..The prognosis of ATL patients should be improved in the near future with clinical applications of novel treatment strategies, including those involving KW-0761 and other promising antibody therapies targeting CD25 or CD30...
  8. ncbi A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL-2Rγ(null) mouse lymphoma model
    Fumihiko Sato
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi, 467 8601, Japan
    Cancer Immunol Immunother 59:1791-800. 2010
    ..In the near future, the efficacy of this type of CDC-enhancing antibody will be determined in clinical trials in humans...
  9. ncbi Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo
    Asahi Ito
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467 8601, Japan
    J Immunol 183:4782-91. 2009
    ..Furthermore, the potent ADCC mediated by defucosylated anti-CCR4 mAb, observed here in vivo in humanized mice, will be exploited in clinical trials in the near future...
  10. ncbi Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome
    Hiroki Yano
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
    Clin Cancer Res 13:6494-500. 2007
    ....
  11. ncbi Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC
    Atsushi Inagaki
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
    Int J Cancer 125:212-21. 2009
    ..The ULBPs could be valuable diagnostic biological markers and significant targets for immunotherapy to improve efficacy not only of rituximab but also of other therapeutic mAbs...
  12. ncbi CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified
    Takashi Ishida
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Clin Cancer Res 10:5494-500. 2004
    ..We suggest that a specific therapy targeting the CCR4 molecule may be developed as an alternative treatment for patients with CCR4-positive tumors...
  13. ncbi Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma
    Toshihiko Ishii
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
    Clin Cancer Res 16:1520-31. 2010
    ..The second aim was to fully elucidate the mechanism of antibody-dependent cellular cytotoxicity (ADCC) mediated by this defucosylated monoclonal antibody...
  14. ncbi The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma
    Takashi Ishida
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan
    Clin Cancer Res 10:7529-39. 2004
    ....
  15. ncbi Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1
    Masaki Ri
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi, Japan
    Cancer Sci 100:341-8. 2009
    ..Taken together, we conclude that bortezomib-induced apoptosis in ATLL and CTCL cells at least partly depends on the upregulation of Noxa and functional repression of Mcl-1, as is also the case in MM and malignant melanoma...
  16. ncbi Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome
    Takashi Ishida
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science, Nagoya 467-8601, Japan
    Clin Cancer Res 9:3625-34. 2003
    ..Multivariate analysis confirmed that CCR4 expression was an independent and significant prognostic factor (P < 0.05). Thus, our finding may provide a novel insight into not only the biological but also the clinical features of ATLL...
  17. ncbi Angioimmunoblastic T-cell lymphoma mice model
    Fumihiko Sato
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, Aichi 467 8601, Japan
    Leuk Res 37:21-7. 2013
    ..This is the first report of reconstituting follicular helper T (TFH) function in AITL cells in an experimental model, and this is consistent with the theory that TFH cell is the cell of origin of AITL tumor cells...
  18. ncbi Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphoma
    Susumu Suzuki
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Japan
    Cancer Sci 103:1764-73. 2012
    ..The present study not only provides a strong rationale for exploiting Tax as a possible target for ATL immunotherapy but also contributes to our understanding of the immunopathogenesis of ATL...
  19. ncbi Regulatory T-cell function of adult T-cell leukemia/lymphoma cells
    Hiroki Yano
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Mizuho chou, Mizuho ku, Nagoya shi, Aichi, Japan
    Int J Cancer 120:2052-7. 2007
    ..e., how HTLV-1-infected cells can survive in the face of host immune responses. It also adds to our understanding of ATLL patients' severely immunocompromised state...
  20. ncbi Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports
    Tatsuya Yoshida
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho chou, Mizuho ku, Nagoya, 467 8601, Japan
    Int J Hematol 91:844-9. 2010
    ..Establishment of a standard strategy to prevent HBV reactivation is important for myeloma patients receiving systemic chemotherapy...
  21. ncbi Prognostic significance of NPM-ALK fusion transcript overexpression in ALK-positive anaplastic large-cell lymphoma
    Chunmei Li
    Department of Pathology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Mod Pathol 20:648-55. 2007
    ..Overexpression of the NPM-ALK fusion transcript may be associated with a poor prognosis of the patients with ALK(+) anaplastic large-cell lymphomas...
  22. ncbi The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarity
    Jianmin Ding
    Department of Medical Oncology and Immunology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
    Blood 114:3325-8. 2009
    ..This finding provides a new insight into the mechanism of disease causation by mutations in the TMD of cytokine/hematopoietic receptors...
  23. ncbi Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors
    Atsushi Inagaki
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku, Nagoya-shi, Aichi, Japan
    Int J Cancer 118:3054-61. 2006
    ..Measurement of serum IL-5 and IL-10 levels is useful for predicting the prognosis and for determining a suitable treatment strategy for ATLL patients...
  24. ncbi Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma
    Hiroki Yano
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan
    Cancer Sci 99:2309-14. 2008
    ..When a combination of CPT-11 and bortezomib was administered, the subcutaneous tumors completely disappeared. Thus, clinical trials on CPT-11 in patients with relapsed or refractory MM are warranted...
  25. ncbi Forkhead box P1 overexpression and its clinicopathologic significance in peripheral T-cell lymphoma, not otherwise specified
    Seiji Yamada
    Department of Pathology, Nagoya City University Graduate School of Medical Sciences, Nagoya 467 8601, Japan
    Hum Pathol 43:1322-7. 2012
    ..The clinicopathologic significance of forkhead box P1 overexpression in peripheral T-cell lymphoma, not otherwise specified, may be different from that in B-cell lymphomas...
  26. ncbi Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma
    Kazuhito Yamamoto
    Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Aichi, Japan
    J Clin Oncol 28:1591-8. 2010
    ..This phase I study assessed the safety, pharmacokinetics, recommended phase II dose and efficacy of KW-0761 in patients with relapsed CCR4-positive adult T-cell leukemia-lymphoma (ATL) or peripheral T-cell lymphoma (PTCL)...
  27. ncbi Immunopathogenesis of lymphoma: focus on CCR4
    Takashi Ishida
    Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho ku, Nagoya, Japan
    Cancer Sci 102:44-50. 2011
    ....
  28. ncbi Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma
    H Inagaki
    Department of Pathology, Nagoya City University Medical School, Nagoya, Japan
    Mod Pathol 13:482-8. 2000
    ..These data suggested that SYT-SSX fusion type is associated with tumor cell proliferative activity and prognosis of patients who have SS...
  29. ncbi Differential expression of dihydropyrimidinase-related protein genes in developing and adult enteric nervous system
    H Inagaki
    Department of Pathology, Nagoya City University Medical School, Mizuho ku, Nagoya 467 8601, Japan
    Histochem Cell Biol 113:37-41. 2000
    ..Northern blot analysis showed that DRPs were differentially expressed in the mouse and human intestines, supporting the results of ISH. These data suggest that DRPs play a role not only in the CNS but also in the ENS...
  30. ncbi Influence of histochemical and immunohistochemical stains on polymerase chain reaction
    T Murase
    Department of Pathology, Nagoya City University Medical School, Nagoya, Japan
    Mod Pathol 13:147-51. 2000
    ..The immunohistochemical visualization with DAB or new fuchsin yields no unfavorable effects. A successful PCR amplification may not be expected in sections that are pretreated in a microwave oven or pressure cooker...
  31. ncbi Prognostic significance of CD44v6 in diffuse large B-cell lymphoma
    H Inagaki
    Department of Pathology, Nagoya City University Medical School, Nagoya, Japan
    Mod Pathol 12:546-52. 1999
    ....
  32. ncbi Thymic sarcomatoid carcinoma with skeletal muscle differentiation: report of two cases, one with cytogenetic analysis
    T Eimoto
    Department of Pathology, Nagoya City University School of Medicine, Kawasumi, Mizuho ku, Nagoya 467 8601, Japan
    Histopathology 40:46-57. 2002
    ..We report two such cases in which the tumour cells showed a prominent rhabdomyoblastic differentiation and analyse whether these tumours retain an epithelial nature at least in part...
  33. ncbi API2-MALT1 fusion transcripts involved in mucosa-associated lymphoid tissue lymphoma: multiplex RT-PCR detection using formalin-fixed paraffin-embedded specimens
    H Inagaki
    Department of Pathology, Nagoya City University Medical School, Nagoya, Japan
    Am J Pathol 158:699-706. 2001
    ..Our multiplex RT-PCR assay, which can be used for routinely-processed paraffin samples, should serve as a useful molecular tool for clarifying the clinicopathological significance of API2-MALT1 fusion in MALT lymphoma...
  34. ncbi Clonality assay of hematopoietic disorders: significance of the buccal epithelium as non-hematopoietic control and of 95% rejection limit as a novel criterion for monoclonality
    H Inagaki
    Department of Pathology, Nagoya City University Medical School, Kawasumi, Mizuho ku, Nagoya 467 8601, Japan
    Jpn J Cancer Res 92:1305-12. 2001
    ....
  35. ncbi CCR4 as a novel molecular target for immunotherapy of cancer
    Takashi Ishida
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-chou, Mizuho-ku, Nagoya-shi Aichi, 467-8601, Japan
    Cancer Sci 97:1139-46. 2006
    ....
  36. ncbi Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland
    M Okabe
    Department of Pathology, Nagoya City University Medical School, Nagoya, Japan
    Mod Pathol 14:1008-14. 2001
    ..These data suggest that p27 may be useful in estimating prognosis of the patients who have mucoepidermoid carcinoma of the intraoral minor salivary gland...
  37. ncbi Frequent occurrence of CCND1 deregulation in patients with early stages of plasma cell dyscrasia
    Kazuhisa Miura
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Science, Mizuho ku, Nagoya 467 8601, Japan
    Cancer Sci 94:350-4. 2003
    ..This suggests to us that cyclin D1 deregulation due to the presence of t(11;14) is involved in the early development of plasma cell neoplasms, and that this event alone is not enough for the development of symptomatic myeloma...
  38. ncbi rDLG6: a novel homolog of Drosophila DLG expressed in rat brain
    H Inagaki
    Department of Chemistry, National Industrial Research Institute of Nagoya, 1 1 Hirate cho, Kita ku, Nagoya, 462 8510, Japan
    Biochem Biophys Res Commun 265:462-8. 1999
    ..GST pull-down assays showed that the PDZ domain of rDLG6 protein binds to the C-terminus of the AMPA (alpha-Amino-3-hydroxy-5-Methyl-isoxazole-4-Propionic Acid) receptor GluR2 subunit...
  39. ncbi Analysis of VH gene rearrangement and somatic hypermutation in Sjogren's syndrome and IgG4-related sclerosing sialadenitis
    H Sakuma
    Department of Pathology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan
    Scand J Immunol 72:44-9. 2010
    ..0001, respectively). This finding suggests that some autoantibodies encoded by germline or less mutated VH genes may fail to be eliminated and could play a role in the development of SS and IgG4-related sclerosing sialadenitis...
  40. ncbi Aldolase C is localized in neuroendocrine cells
    H Inagaki
    Department of Gastroenterological Surgery, Aichi Cancer Center Hospital, Nagoya, Japan
    Experientia 44:749-51. 1988
    ..Aldolase C was found to be localized in various types of neuroendocrine cells; in the pituitary gland, thyroid, pancreas, adrenal gland, bronchus, and gastrointestinal tract...
  41. ncbi Osteoprotegerin levels before and after renal transplantation
    T Sato
    Department of Transplant Surgery, Nagoya 2nd Red Cross Hospital, Nagoya, Japan
    Am J Kidney Dis 38:S175-7. 2001
    ..Serum OPG declines for the first 2 weeks after RTX owing to functioning allograft and decreases again for the next 2 weeks because of steroids and possible immunosuppressive agents...
  42. ncbi Multiple myeloma oncogene 1 (MUM1)/interferon regulatory factor 4 (IRF4) upregulates monokine induced by interferon-gamma (MIG) gene expression in B-cell malignancy
    M Uranishi
    Department of Internal Medicine and Molecular Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Leukemia 19:1471-8. 2005
    ..Leukemia (2005) 19, 1471-1478. doi:10.1038/sj.leu.2403833; published online 16 June 2005...
  43. ncbi Effects of contractile activity on mitochondrial transcription factor A expression in skeletal muscle
    J W Gordon
    Kinesiology and Health Science, Faculty of Pure and Applied Science, York University, Toronto, Ontario, Canada
    J Appl Physiol 90:389-96. 2001
    ..This was accompanied by increased mitochondrial transcript levels and elevated COX activity. These data support the role of Tfam as a regulatory protein involved in contractile activity-induced mitochondrial biogenesis...
  44. ncbi Differences in radiographic findings between scaphoid fracture patterns
    H Inagaki
    Department of Hand Surgery, Nagoya University School of Medicine, Nagoya 466 8550, Japan
    Hand Surg 9:197-202. 2004
    ..No differences were evident between the two fracture patterns with respect to prevalence of dorsal intercalated segment instability deformity...